| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 云南沃森生物技术股份有限公司是一家专业从事人用疫苗产品研发、生产、销售的生物制药企业.公司主要产品是各类安全有效、品质优异、技术先进的人用疫苗.本公司现拥有一个先进的疫苗中试研发中心,建成了一个现代化疫苗生产基地,构建了一个覆盖全国29个省区、2,000多个县市的营销网络.本公司一直专注于疫苗领域发展,凭借对行业的深刻理解和敏锐的洞察力,确立了以市场需求为导向,以"产品升级换代"和"填补国内空白"为主的产品研发战略,精心构建了技术领先的研发技术平台和高效的研发管理体系,截至2010年已在13个疫苗产品的开发研制上取得显著的成果,同时储备了一批品种丰富、结构合理且市场前景广阔的产品梯队.本公司自主研发、拥有自主知识产权的第一个疫苗Hib及第二个疫苗冻干A、C脑膜炎球菌多糖结合疫苗分别已于2007年9月、2009年9月通过自行产业化成功投产上市,通过积极贯彻本公司确立的以品牌营销为导向、渠道网络覆盖为基础、快速覆盖抢占终端的营销策略,上述两个产品上市以来均取得良好的市场业绩.随着公司后续储备疫苗不断产业化,本公司已成为国内最具有持续成长活力的生物制药企业之一。 | ||||||||||||||||||||||||
| Main Business | 从事疫苗、单抗药物和血液制品的研发、生产和销售业务。 | ||||||||||||||||||||||||
| Legal Representative | 李云春 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 刘宇然 | ||||||||||||||||||||||||
| Solicitors | 北京大成律师事务所 | ||||||||||||||||||||||||
| Auditors | 信永中和会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0871-68312779 | ||||||||||||||||||||||||
| Fax No | 0871-68312779 | ||||||||||||||||||||||||
| Website | www.walvax.com | ||||||||||||||||||||||||
| ir@walvax.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 12/11/2010 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.262 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.010 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.817 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 18.321B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |